AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01992952
Drug: AZD5363
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
Trial: NCT01992952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
Trial: NCT03844906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in combination with Ketamine
Trial: NCT03575702
Drug: Uritos®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablets 0.1 mg
Trial: NCT03575702
Drug: Urotol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film coated tablets, 2 mg
Trial: NCT01049217
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
Trial: NCT02224014
Drug: Lendormin D tablets
RxNorm normalized name: D-biotin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02872246
Drug: SPF 15 Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
Trial: NCT01685671
Drug: NESP 60μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated NESP 60μg once subcutaneously
Trial: NCT01685671
Drug: CKD-11101 60μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated CKD-11101 60μg once subcutaneously
Trial: NCT01381393
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
Trial: NCT00539773
Drug: BCG, Interferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT01744496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches match the size of active patches 20 cm\^2, 30 cm\^2, or 40 cm\^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
Trial: NCT00278564
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02775695
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
Trial: NCT00141102
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are assigned to one of two groups in parallel for the duration of the study
Trial: NCT04308161
Drug: BBC oral spray
RxNorm normalized name: SNAIL, UNSPECIFIED 18.05 g in 40 g / TITANIUM DIOXIDE 3.6 g in 40 g / ZINC OXIDE 2.52 g in 40 g / ARBUTIN 0.8 g in 40 g / ADENOSINE 0.016 g in 40 g TOPICAL CREAM [SKIN79 SNAIL NUTRITION BBCREAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthetics and anti-inflammatory agent
Trial: NCT04308161
Drug: Oracure gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical analgesic gel
Trial: NCT02347046
Drug: FYU-981, (Oral single dosing)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FYU-981, (Oral single dosing)
Trial: NCT02682745
Drug: TALION tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug: TALION tab, 1T, every 12 hours, oral administration
Trial: NCT00513643
Drug: human regular insulin
RxNorm normalized name: Human regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6, 12 and 24 IU sc
Trial: NCT03301896
Drug: LHC165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHC165 intratumoral injection
Trial: NCT01781507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This placebo ( sugar pill) will provide the negative control for this study
Trial: NCT00503828
Drug: Derris scandens Benth extracts
RxNorm normalized name: Senecio scandens flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
Trial: NCT00503828
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen 500 mg/day for 4 weeks
Trial: NCT01108939
Drug: Antimalarial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03504917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo.
Trial: NCT00822523
Drug: Botulinum Toxin, Type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 units, single dose, intramuscular in right EDB muscle
Trial: NCT00822523
Drug: Botulinum Toxin, Type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 units, single dose, intramuscular to right EDB muscle
Trial: NCT00141102
Drug: Diclofenac + Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants are assigned to one of two groups in parallel for the duration of the study
Trial: NCT01000285
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01300962
Drug: BMK120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
Trial: NCT01300962
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
Trial: NCT01300962
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
Trial: NCT01598311
Drug: CB-183,315
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-183,315 250 mg white coated tablet over-encapsulated in a size 00 opaque hard gelatin capsule.
Trial: NCT01598311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo size 00 opaque hard gelatin capsules.
Trial: NCT05380778
Drug: Deep anesthesia
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia~Other Names:~BIS lower than or equal to 45
Trial: NCT05380778
Drug: Shallow anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Low dose propofol, fentanyl and sevoflurane Shallow Anesthesia~Other Names:~BIS above 45
Trial: NCT04308343
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drugs to treat undisturbed ectopic pregnancies
Trial: NCT01372423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mcg capsules
Trial: NCT00691028
Drug: TA-650 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Trial: NCT00691028
Drug: TA-650 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Trial: NCT00691028
Drug: TA-650 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
Trial: NCT04351737
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To reduce post-surgical pain and inflammation in patients who undergo bilateral pterygium surgery.
Trial: NCT03439254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily.
Trial: NCT02002650
Drug: Pre-ERCP rectal Indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal Indomethacin was administrated within 30min before ERCP in all patients.
Trial: NCT02002650
Drug: Post-operational Rectal Indomethacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
Trial: NCT01528124
Drug: LY3025876
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as a subcutaneous injection
Trial: NCT01528124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as a subcutaneous injection
Trial: NCT04145336
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
Trial: NCT03531970
Drug: 2% lidocaine with 1:80,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthetic solution
Trial: NCT03531970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02136693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 g /day of inert compound for 180 days after STARR
Trial: NCT01589237
Drug: LCQ908
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00824785
Drug: epirubicin, oxaliplatin, capecitabine (EOX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
Trial: NCT02585869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blinded capsule and tablets, once daily, 84 days
Trial: NCT03929744
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03929744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03929744
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03029351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
Trial: NCT01441986
Drug: Pacebo 1 (placebo for Amantadine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talets for oral use; single dose.
Trial: NCT01441986
Drug: Placebo 2 (fo Dextromethorphan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsles for oral administration; single dose.
Trial: NCT03307174
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03228901
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00863707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01893294
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00339456
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00816400
Drug: MEDI-575
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-575 as an IV infusion
Trial: NCT03116737
Drug: Benzocaine Otic Solution
RxNorm normalized name: Benzocaine Otic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03116737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00114413
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Used for both regular asthma control and as a rescue inhaler
Trial: NCT00140192
Drug: creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03312283
Drug: QL1205
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
Trial: NCT00116883
Drug: GW685698X aqueous nasal spray
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03753659
Drug: Transarterial Chemoembolisation (TACE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to Investigator's choice, TACE using drug eluting beads can be performed combined with RFA, MWA or brachytherapy
Trial: NCT04221399
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Once daily, Single dose
Trial: NCT04221399
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, Once daily, Multiple dose
Trial: NCT01218893
Drug: Malarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
Trial: NCT02270918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00913237
Drug: Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)
RxNorm normalized name: desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913237
Drug: Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)
RxNorm normalized name: desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02240667
Drug: Vitamin K antagonists
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: International Normalized Ratio (INR) 2-3
Trial: NCT04318067
Drug: Melatonin 3 mg
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin 3 mg is given ones a day - at bedtimes for 6 month
Trial: NCT00461032
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to montelukast QD for 8 weeks
Trial: NCT01837745
Drug: rhTSH stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
Trial: NCT04067648
Drug: Sufentanil Injection
RxNorm normalized name: sufentanil Injection
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: three doses of sufentanil was intravenously given during anesthesia induction
Trial: NCT00238147
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00182663
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01143779
Drug: FLT-PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
Trial: NCT02204943
Drug: Administration of radium-223
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
Trial: NCT02039258
Drug: CANA/MET XR FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
Trial: NCT00001781
Drug: CGP 77116
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01563523
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
Trial: NCT00449553
Drug: Pioglitazone and sulphonylurea
RxNorm normalized name: glimepiride and pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
Trial: NCT00449553
Drug: Pioglitazone and sulphonylurea
RxNorm normalized name: glimepiride and pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
Trial: NCT04458363
Drug: Standard COVID-19 therapies
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If clinical status permits, administration of additional COVID-19 therapies should be delayed 48 hours or more from CP infusion completion. Supportive care will be administered by best clinical practice.
Trial: NCT00277706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo; self administration for 6 weeks
Trial: NCT03112564
Drug: Sevoflurane 8% + Intravenous fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
Trial: NCT04288999
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy: CAPOX or mFOLFOX6 or capecitabine or 5-FU+l-LV~CAPOX: oxaliplatin (130 mg/m2/day, day 1) and oral capecitabine (2000 mg/m2/day, twice daily, days 1-14)~mFOLOX6: oxaliplatin 85 mg/m2 with l-LV 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion over 46 hours.~Capecitabine: 2000 mg/m2/day, twice daily, days 1-14~5-FU+l-LV: leucovorin 200 mg/m2 for over 2 hours followed by a fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion for over 46 hours
Trial: NCT03558373
Drug: Immunosuppressive
RxNorm normalized name: Immunosuppressive acidic protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapies
Trial: NCT00008073
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03046693
Drug: Group B placebo oral tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be repackaged and given to Group B for 60 days
Trial: NCT02729285
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
Trial: NCT01590082
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I.
Trial: NCT01054170
Drug: AZD9668
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 30 mg oral tablets twice daily (bid) for 12 weeks
Trial: NCT01054170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
Trial: NCT01237587
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02851485
Drug: GLPG1972 600 mg oral tablet fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosing after overnight fasting
Trial: NCT02851485
Drug: GLPG1972 600 mg oral tablet fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosing after high-fat high-calorie breakfast
Trial: NCT00279032
Drug: GW406381
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00456885
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily injection of placebo
Trial: NCT02045056
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no